Fox Run Management’s Cytokinetics CYTK Stock Holding History

Fox Run Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$559K	Buy	+8,477	New	+$646K	0.07%	536
2025 Q2	–	Sell	-23,181	Closed	-$932K	–	943
2025 Q1	$932K	Buy	+23,181	New	+$1.07M	0.14%	228
2024 Q4	–	Sell	-3,870	Closed	-$204K	–	929
2024 Q3	$204K	Buy	+3,870	New	+$216K	0.05%	667
2022 Q4	–	Sell	-7,665	Closed	-$371K	–	677
2022 Q3	$371K	Buy	7,665 +1,845	+32%	+$88.8K	0.14%	278
2022 Q2	$229K	Buy	+5,820	New	+$234K	0.11%	385
2021 Q3	–	Sell	-16,978	Closed	-$336K	–	495
2021 Q2	$336K	Buy	+16,978	New	+$399K	0.31%	136
2018 Q3	–	Sell	-31,627	Closed	-$263K	–	623
2018 Q2	$263K	Buy	31,627 +20,405	+182%	+$170K	0.08%	485
2018 Q1	$81K	Sell	11,222 -10,953	-49%	-$93.9K	0.02%	685
2017 Q4	$181K	Buy	+22,175	New	+$252K	0.05%	587
2017 Q3	–	Sell	-36,000	Closed	-$436K	–	710
2017 Q2	$436K	Buy	+36,000	New	+$500K	0.15%	271
2016 Q1	–	Sell	-17,200	Closed	-$180K	–	443
2015 Q4	$180K	Buy	+17,200	New	+$169K	0.14%	319

Other funds holding CYTK

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Fox Run Management's CYTK Position: Q3 2026 in Review

Fox Run Management opened a new position in Cytokinetics (CYTK) in Q3 2026: 8,477 shares worth $559K. The stake represents 0.07% of the portfolio and ranks #536 among its holdings. This is a return to the name: Fox Run Management previously reported a position in CYTK as recently as Q1 2025.

Fox Run Management first reported a position in CYTK in Q4 2015 and has held it in 11 quarters since. The position peaked at $932K in Q1 2025. 348 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

Fox Run Management held 8,477 shares of Cytokinetics worth $559K as of Q3 2026.
Cytokinetics was a new Fox Run Management position in Q3 2026.
Cytokinetics made up 0.07% of Fox Run Management's portfolio in Q3 2026, its #536 holding.
Fox Run Management first reported a position in Cytokinetics in Q4 2015 and has held it in 11 quarters since.
Fox Run Management's Cytokinetics position peaked at $932K in Q1 2025.
348 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Fox Run Management's 13F filing for Q3 2026, filed 12 Nov 2026.